Immune Activation in HIV-Infected Patients Treated with Different ARV Regimens

Autor: Bray Dorothy, Marinella Lauriola, Massimo Coen, Daria Trabattoni, Roberta Terzi, Mario Clerici, Sergio Lo Caputo, Elisabetta Chiesa, Alessia Uglietti, M. Gennaro, Renato Maserati

Publikováno v: World Journal of AIDS. :97-102

Objectives: To evaluate the effects of starting therapy with either Truvada (TVD) or Combivir (CBV) in combination with Efavirenz (EFV) or a boosted Protease Inhibitor (LPV/r, ATV/r, fAPV/r and SQV/r) on clinical, immunological, and virological param

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6739eb511b31a47691652ce1a9f541af
https://doi.org/10.4236/wja.2012.22013

Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects

Autor: Paola Cicconi, Marco Bongiovanni, Elisabetta Chiesa, Teresa Bini, Fulvio Adorni, Antonella d'Arminio Monforte

Publikováno v: Antiviral research
62 (2004): 53–56. doi:10.1016/j.antiviral.2003.12.002
info:cnr-pdr/source/autori:Bongiovanni M.; Bini T.; Chiesa E.; Cicconi P.; Adorni F.; D'Arminio Monforte A./titolo:Lopinavir%2Fritonavir vs. indinavir%2Fritonavir in antiretroviral naive HIV-infected patients: Immunovirological outcome and side effects/doi:10.1016%2Fj.antiviral.2003.12.002/rivista:Antiviral research (Print)/anno:2004/pagina_da:53/pagina_a:56/intervallo_pagine:53–56/volume:62

We compared immunovirological outcomes and toxicities of HAART regimens including LPV/r and IDV/r in antiretroviral naïve HIV-1 patients. We retrospectively selected 55 patients starting LPV/r and 52 starting IDV/r as first-line HAART. Immunovirolog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::122713a7328ae99c8ae2794973f2b969
https://doi.org/10.1016/j.antiviral.2003.12.002

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection

Autor: Mauro Moroni, C. Abeli, Teresa Bini, d'Arminio Monforte A, L. Testa, Elisabetta Chiesa, Claudia Balotta, Massimo Musicco, Salvatore Sollima, Fulvio Adorni, Moscatelli Gc, Massimo Galli, Stefano Rusconi

Publikováno v: AIDS (Lond.) 12 (1998): 1631–1637. doi:10.1097/00002030-199813000-00010
info:cnr-pdr/source/autori:D'Arminio Monforte A.; Testa L.; Adorni F.; Chiesa E.; Bini T.; Moscatelli G.C.; Abeli C.; Rusconi S.; Sollima S.; Balotta C.; Musicco M.; Galli M.; Moroni M./titolo:Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection/doi:10.1097%2F00002030-199813000-00010/rivista:AIDS (Lond.)/anno:1998/pagina_da:1631/pagina_a:1637/intervallo_pagine:1631–1637/volume:12

Objective: To verify the effectiveness of highly active antiretroviral therapy (HAART) and to identify any factors predictive of clinical outcome in a clinical setting. Design: Observational study. Methods: Treatment failure (i.e., the occurrence of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f19f4a2868880c7205a5f5ad902e628f
https://doi.org/10.1097/00002030-199813000-00010

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone

Autor: A. De Luca, Cristina Mussini, Elisabetta Chiesa, Antonella Castagna, A. Matti, Carlo Torti, C. Abeli, Nicola Gianotti, Paola Cicconi, A d'Arminio Monforte, Marco Bongiovanni, Amedeo Capetti, Mauro Zaccarelli, A. Di Biagio, Andrea Antinori, Patrizia Marconi, Valeria Tirelli, Paola Nasta, Francesca Gatti

We evaluated the efficacy of tenofovir (TDF) - and didanosine (ddI)-containing backbones in HIV-infected experienced subjects. We included in the study 245 subjects who started a TDF/ddI-containing HAART with HIV-RNA > 3 log10cp/ml and an available g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b37610e587639e867978f560da0f29bd
https://hdl.handle.net/11567/991995

Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART

Autor: Paola Cicconi, Teresa Bini, Patrizia Biasi, Elisabetta Chiesa, Antonio Di Biagio, Paola Meraviglia, Federica Tordato, Amedeo Capetti, Antonella d'Arminio Monforte, Marco Bongiovanni

Publikováno v: The Journal of antimicrobial chemotherapy. 55(6)

The long-term virological efficacy of lopinavir/ritonavir-containing highly active antiretroviral therapy (HAART) in HIV-infected patients failing a first-line protease inhibitor (PI)-based regimen is still unclear.An observational study was carried

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f23f87043ccb542f42eb600d14f8914
https://pubmed.ncbi.nlm.nih.gov/15824089